Lian Li

Dr. Lian Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
MZMinglu Zhou
Minglu Zhou
QZQingting Zuo
Qingting Zuo
YHYuan Huang
Yuan Huang
LLLian Li
Lian Li
Tumor recurrence and metastasis is the leading cause of mortality for postoperative breast cancer patients. However, chemotherapy intervention after surgery is often unsatisfactory, because residual microtumors are difficult to target and require frequent administration. Here, an all-in-one and once-for-all drug depot based on in situ-formed hydrogel was applied to fit the irregular surgical trauma, and enable direct contact with residual tumors and sustained drug release. Our immunological analysis after resection of orthotopic breast tumor revealed that postsurgical activation of CXCR4–CXCL12 signal exacerbated the immunosuppression and correlated with adaptive upregulation of PD-L1 in recurrent tumors. Thus, a multifunctional hydrogel toolkit was developed integrating strategies of CXCR4 inhibition, immunogenicity activation and PD-L1 blockade. Our results showed that the hydrogel toolkit not only exerted local effect on inhibiting residual tumor cell “seeds” but also resulted in abscopal effect on disturbing pre-metastatic “soil”. Furthermore, vaccine-like effect and durable antitumor memory were generated, which resisted a secondary tumor rechallenge in 100% cured mice. Strikingly, one single dose of such modality was able to eradicate recurrent tumors, completely prevent pulmonary metastasis and minimize off-target toxicity, thus providing an effective option for postoperative intervention.

1 June 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
MZMinglu Zhou
Minglu Zhou
CLChaohui Luo
Chaohui Luo
ZZZhou Zhou
Zhou Zhou
LLLian Li
Lian Li
YHYuan Huang
Yuan Huang

2 December 2021 in Small
Verified
Journal Article
Closed access
PDF file
YXYucheng Xiang
Yucheng Xiang
LCLiqiang Chen
Liqiang Chen
CLChendong Liu
Chendong Liu
XYXiaoli Yi
Xiaoli Yi
LLLian Li
Lian Li
YHYuan Huang
Yuan Huang

28 March 2022 in ACS Nano
Verified
Journal Article
Closed access
JLJunlin Li
Junlin Li
PZPing Zhang
Ping Zhang
MZMinglu Zhou
Minglu Zhou
CLChendong Liu
Chendong Liu
YHYuan Huang
Yuan Huang
LLLian Li
Lian Li

8 June 2023 in Advanced Science
Verified
Journal Article
Open access
XSXinran Shen
Xinran Shen
YDYudi Deng
Yudi Deng
LCLiqiang Chen
Liqiang Chen
CLChendong Liu
Chendong Liu
LLLian Li
Lian Li
YHYuan Huang
Yuan Huang
Strategies that induce dysfunction in the endoplasmic reticulum (ER) hold great promise for anticancer therapy, but remain unsatisfactory due to the compensatory autophagy induction after ER disruption. Moreover, as autophagy can either promote or suppress cell survival, which direction of autophagy better suits ER‐targeting therapy remains controversial. Here, a targeted nanosystem is constructed, which efficiently escorts anticancer therapeutics into the ER, triggering substantial ER stress and autophagy. Concurrently, an autophagy enhancer or inhibitor is combined into the same nanoparticle, and their impacts on ER‐related activities are compared. In the orthotopic breast cancer mouse model, the autophagy enhancer increases the antimetastasis effect of ER‐targeting therapy and suppresses over 90% of cancer metastasis, while the autophagy inhibitor has a bare effect. Mechanism studies reveal that further enhancing autophagy accelerates central protein snail family transcriptional repressor 1 (SNAI1) degradation, suppressing downstream epithelial–mesenchymal transition, while inhibiting autophagy does the opposite. With the same trend, ER‐targeting therapy combined with an autophagy enhancer provokes stronger immune response and tumor inhibition than the autophagy inhibitor. Mechanism studies reveal that the autophagy enhancer elevates Ca2+ release from the ER and functions as a cascade amplifier of ER dysfunction, which accelerates Ca2+ release, resulting in immunogenic cell death (ICD) induction and eventually triggering immune responses. Together, ER‐targeting therapy benefits from the autophagy‐enhancing strategy more than the autophagy‐inhibiting strategy for antitumor and antimetastasis treatment.

29 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMinglu Zhou
Minglu Zhou
CLChendong Liu
Chendong Liu
BLBo Li
Bo Li
JLJunlin Li
Junlin Li
PZPing Zhang
Ping Zhang
LLLian Li
Lian Li
The binding of therapeutic antagonists to their receptors often fail to translate into adequate manipulation of downstream pathways. To fix this ‘bug’, here we report a strategy that stitches cell surface ‘patches’ to promote receptor clustering, thereby synchronizing subsequent mechano-transduction. The “patches” are sewn with two interactable nanothreads. In sequence, Nanothread-1 strings together adjacent receptors while presenting decoy receptors. Nanothread-2 then targets these decoys multivalently, intertwining with Nanothread-1 into a coiled-coil supramolecular network. This stepwise actuation clusters an extensive vicinity of receptors, integrating mechano-transduction to disrupt signal transmission. When applied to antagonize chemokine receptors CXCR4 expressed in metastatic breast cancer of female mice, this strategy elicits and consolidates multiple events, including interception of metastatic cascade, reversal of immunosuppression, and potentiation of photodynamic immunotherapy, reducing the metastatic burden. Collectively, our work provides a generalizable tool to spatially rearrange cell-surface receptors to improve therapeutic outcomes.